1	Supplementary Information
2	Genome-wide association studies of lifetime and frequency cannabis use in 131,895
3	individuals
4	
5	Hayley H A Thorpe, PhD ¹ , Pierre Fontanillas, PhD ² , John J Meredith, BSc ³ , Mariela V Jennings,
6	BSc ³ , Renata B Cupertino, PhD ³ , Shreya Pakala, BSc ³ , 23andMe Research Team ² , Sarah L
7	Elson, PhD ² , Jibran Y Khokhar, PhD ¹ , Lea K Davis ^{4,5,6} , PhD, Emma C Johnson, PhD ⁷ , Abraham
8	A Palmer, PhD ^{3,8} , & Sandra Sanchez-Roige, PhD ^{3,5,8*}
9	¹ Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, Western
10	University, London, ON, Canada.
11	² 23andMe, Inc., Sunnyvale, CA, USA
12	³ Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
13	⁴ Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN,
14	USA
15	⁵ Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
16	⁶ Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center,
17	Nashville, TN, USA
18	⁷ Department of Psychiatry, Washington University School of Medicine, St. Louis, MO USA
19	⁸ Institute for Genomic Medicine, University of California San Diego, La Jolla, CA, USA
20	
21	Corresponding Author:
22	Sandra Sanchez-Roige, PhD
23	Department of Psychiatry, University of California San Diego
24	9500 Gilman Drive, La Jolla, CA, USA, 92093
25	Phone: +1-619-874-1426
26	Email: sanchezroige@ucsd.edu

27 Supplementary Methods

28 Analysis of local ancestry

29 We performed lifetime cannabis use GWAS (N=131,895) and frequency of cannabis use 30 GWAS (N=73,374) on 23andMe, Inc. participants classified as being of European ancestry. Ancestry falls along a spectrum^{1,2}; each individual was clustered based on genetic similarity to a 31 32 reference panel using local ancestry analysis³. Briefly, the 23andMe algorithm first partitions 33 phased genomic data into short windows of about 300 SNPs. Within each window, we use a support vector machine to classify individual haplotypes into one of 31 reference populations 34 (https://www.23andme.com/ancestry-composition-guide/). 35 The support vector machine 36 classifications are fed into a hidden Markov model that accounts for switch errors and incorrect 37 assignments, and gives probabilities for each reference population in each window. The reference 38 population data is derived from public datasets (the Human Genome Diversity Project, HapMap, 39 and 1000 Genomes), as well as 23 and Me customers who have reported having four grandparents 40 from the same country.

- 41
- Ancestries are defined as follows:

Ancestry	Classification Criteria
European	European + Middle Eastern > 0.97, European > 0.90
East Asian	East Asian + Southeast Asian > 0.97
South Asian	South Asian > 0.97
Middle Eastern (& North African)	Middle Eastern + European > 0.97, Middle Eastern > 0.90
African American + Latin	European + African + East Asian + Native American +
American	Middle Eastern > 0.90, African + Native American > 0.01

42 Genome-wide association and secondary analyses

43 DNA extraction and genotyping were performed from saliva samples by clinical 44 laboratories CLIA-certified and CAP-accredited by the Laboratory Corporation of America. 45 23andMe, Inc. conducted all quality control, imputation, and univariate genome-wide analyses as 46 previously described (see **Supplementary Table 3** for SNPs analyzed following quality control 47 and imputation)^{4,5}. Participants were genotyped on one of five Illumina genotyping platforms, 48 containing between 550,000 to 950,000 variants, for a total of 1.6 million genotyped variants. 49 Samples were genotyped on one of five genotyping platforms. The V1 and V2 platforms were 50 variants of the Illumina HumanHap550 + BeadChip, including about 25,000 custom SNPs 51 selected by 23andMe, with a total of ~560,000 SNPs. The V3 platform was based on the Illumina 52 OmniExpress + BeadChip, with custom content to improve the overlap with our V2 array, with a 53 total of ~950,000 SNPs. The V4 platform is a fully custom array, including a lower redundancy 54 subset of V2 and V3 SNPs with additional coverage of lower-frequency coding variation, and ~570,000 SNPs. The v5 platform, in current use, is an Illumina Infinium Global Screening Array 55 56 (~640,000 variants) supplemented with ~50,000 variants of custom content. Samples that failed 57 to reach 98.5% call rate were excluded from the study. Samples that failed to reach 98.5% call 58 rate were re-analyzed^{6,7}. Variants were imputed based on an imputation panel combining 1000 59 Genomes Phase 3, UK10K and the Human Reference Consortium (HRC). About 64.4 million 60 variants were then imputed against the HRC panel, augmented by a single unified imputation 61 reference panel combining the May 2015 release of the 1000 Genomes Phase 3 haplotypes with 62 the UK10K imputation reference panel for variants not present in the HRC. Imputed variants with low imputation quality ($r^2 < 0.50$ averaged across batches or a minimum $r^2 < 0.30$), or with evidence 63 of batch effects (p<1.00E-50) were removed^{6,7}. A total of 1.3 million genotyped and 30.5 million 64 65 imputed variants passed the pre- and post-GWAS guality controls. We furthermore filtered out 66 variants with minor allele frequency (**MAF**) < 0.1%, which are extremely sensitive to quantitative 67 trait over-dispersion, reducing to 14.1 million variants available for follow-up analyses. Principal components were computed using ~65,000 high-quality genotyped variants present in all fivegenotyping platforms.

70 A maximal set of unrelated individuals was chosen for the analysis using a segmental 71 identity-by-descent (IBD) estimation algorithm⁸ to ensure that only unrelated individuals were 72 included in the sample. Individuals were defined as related if they shared more than 700 cM IBD, 73 including regions where the two individuals shared either one or both genomic segments IBD. 74 This level of relatedness (~20% of the genome) corresponds to approximately the minimal 75 expected sharing between first cousins in an outbred population. For the lifetime cannabis use 76 binary phenotype, if a case was found to be related to a control, the case was preferentially kept 77 in the sample. The 23 and Me GWAS pipeline performs linear regression and assumes an additive model for allelic effects⁹⁻¹². Age (inverse-normal transformed), sex, the top five principal genotype 78 79 components, and indicator variables for genotype platforms were applied as covariates and p-80 values were corrected for genomic control. We imputed participant genotype data against the 81 September 2013 release of 1000 Genomes phase 1 version 3 reference haplotypes. We phased 82 and imputed data for each genotyping platform separately. We phased using an internally 83 developed phasing tool, Finch, which implements the Beagle haplotype graph-based phasing 84 algorithm, modified to separate the haplotype graph construction and phasing steps. In 85 preparation for imputation, we split phased chromosomes into segments of no more than 10,000 86 genotyped SNPs, with overlaps of 200 SNPs. We excluded SNPs of low genotyping quality, 87 including those that failed a Mendelian transmission test in trios (p < 1.00E-20) or with large allele 88 frequency discrepancies compared to European 1000 Genomes reference data, failed Hardy-Weinberg test (p<1.00E-20), failed batch effects test (ANOVA p<1.00E-20), or had a call rate 89 90 <90%. Frequency discrepancies were identified by computing a 2 x 2 table of allele counts for 91 European 1000 Genomes samples and 2000 randomly sampled 23andMe research participants with European ancestries, and identifying SNPs with a $\chi^2 p < 10E-15$. We imputed each phased 92

segment against all-ethnicity 1000 Genomes haplotypes (excluding monomorphic and singleton
sites) using Minimac2¹³, using 5 rounds and 200 states for parameter estimation.

For the X chromosome, we built separate haplotype graphs for the non-pseudoautosomal region and each pseudoautosomal region, and these regions were phased separately. We then imputed males and females together using Minimac2, as with the autosomes, treating males as homozygous pseudo-diploids for the non-pseudoautosomal region.

For tests using imputed data, we use the imputed dosages rather than best-guess genotypes. We imputed HLA allele dosages from SNP genotype data using HIBAG. We imputed alleles for HLA-A, B, C, DPB1, DQA1, DQB1, and DRB1 loci at four-digit resolution. To test associations between HLA allele dosages and phenotypes, we performed linear regression using the same set of covariates used in the SNP based GWAS. We performed separate association tests for each imputed allele. HLA analysis did not identify any significant signal and hence are not described in the main text.

106 Genetic correlation, PheWAS, and LabWAS traits

107 Genetic correlations were conducted using a set of 292 summary statistics across 22 108 health, psychiatric, and anthropomorphic categories. Summary statistics related to health 109 included 21 cancer, 16 cardiovascular, 10 immune & inflammation, 10 metabolic, 9 110 gastrointestinal, 8 neurological, 6 pain, and 15 other health traits. Summary statistics related to 111 psychiatric health included 39 substance use & misuse, 23 anxiety & stress disorder, 23 bipolar 112 & depression, 12 cognitive & executive function, 8 psychosis, 4 suicide, and 17 other psychiatric 113 traits. Summary statistics related to anthropologic characteristics included 28 personality, 16 114 lifestyle/events, 7 diet, 7 physical, 6 sleep, 4 neuroimaging, and 3 longevity traits.

Following exclusion of phecodes with insufficient data, we retained 1,405 phenotypes for the PheWAS analysis. Disease phenotypes included 149 circulatory system, 131 digestive, 129 genitourinary, 123 endocrine/metabolic, 120 neoplasms, 96 musculoskeletal, 92 sense organs, injuries & poisonings, 77 respiratory, 72 dermatological, 71 neurological, 70 psychiatric

- disorders, 47 infectious diseases, 45 hematopoietic, 36 symptoms, 35 congenital anomalies, and
- 120 35 pregnancy complications.
- 121 We explored associations with cannabis PGS using 314 LabWAS phenotypes. LabWAS
- 122 phenotypes included 74 immune, 68 metabolic, 56 blood, 24 cardiovascular, 23 urinary, 20
- 123 endocrine, 16 toxicology/pharmacology, 14 other, 6 cancer, 6 kidney, 6 liver, and 1 OB/GYN.

124 Polygenic Score Prediction in All of Us

- 125 The following concept ID codes available in *All of Us* (AoU) were used to create cohorts
- 126 of participants with cannabis use traits of interest:

Concept ID(s)	Question/Criteria				
Lifetime Cannabis Use					
1585636	Answered MARIJUANA to the question "In your LIFETIME, which of the following substances have you ever used?"				
Daily Cannabis Use					
1585650	Answered DAILY to the question "In the PAST THREE MONTHS, how often have you used Marijuana (cannabis, pot, grass, hash, weed, etc.)?"				
Problematic Cannabis Use					
434327	Cannabis abuse EHR				
440387	Cannabis dependence EHR				
440996	Cannabis dependence in remission EHR				
433452	Cannabis dependence, continuous EHR				
437838	Cannabis dependence, episodic EHR				
4323639	Cannabis misuse EHR				
4103419	Nondependent cannabis abuse EHR				
435231	Nondependent cannabis abuse in remission EHR				
434019	Nondependent cannabis abuse, continuous EHR				
434328	Nondependent cannabis abuse, episodic EHR				

127 To calculate liability scale R^2 estimates for polygenic prediction based on Lee et al. ¹⁴, the

128 estimated prevalence of cannabis use traits in the US population was obtained from the literature

129 for individuals over 18 years old.

Trait	Estimate (%)	Criteria
Lifetime cannabis use ¹⁵	50.30	Answering yes to the question "Have you ever, even once, used marijuana or any cannabis product?" in the National Survey on Drug Use and Health Survey
Daily or almost daily cannabis use ¹⁵	25.10	Reporting using marijuana on ≥20 days in the past month in the National Survey on Drug Use and Health Survey
DSM-5 CUD ¹⁶	6.27	≥2 out of 11 diagnostic criteria within a 12-month period in the, aggregated with prior diagnosis history in the National Epidemiologic Survey on Alcohol and Related Conditions-III

131 Supplementary Figures



133 Supplementary Figure 1. Participant cannabis use by sex and age group. A) Proportion of

134 reported lifetime cannabis use by sex. B) Proportion of frequency of cannabis use by sex. C)

- 135 Proportion of reported lifetime cannabis use by age groups. **D)** Proportion of reported frequency
- 136 of cannabis use by age group.

137





139 Supplementary Figure 2. Q-Q plots for A) lifetime cannabis use and B) frequency of cannabis

140 use.





Supplementary Figure 3. Locus zoom plot focusing on SNP A) rs11922956 on chromosome 3 and B) rs12673181 on chromosome 7. These plots were generated using LocusZoom ¹⁷. The $log_{10}(p$ -value) is shown on the left *y*-axis; position in Mb is on the *x*-axis. Recombination rates (expressed in centiMorgans cM per Mb; NCBI Build GRCh37; highlighted in blue) are shown on the right *y*-axis. Pairwise linkage disequilibrium (r²) of each SNP with the top SNP in the region is indicated by its color. Crossed points represent imputed SNPs, circles represent directly genotyped SNPs.



Supplementary Figure 4. Locus zoom plot focusing on SNP rs4856591 on chromosome 3. This plot was generated using LocusZoom ¹⁷. The $-\log_{10}(p$ -value) is shown on the left *y*-axis; position in Mb is on the *x*-axis. Recombination rates (expressed in centiMorgans cM per Mb; NCBI Build GRCh37; highlighted in blue) are shown on the right *y*-axis. Pairwise linkage disequilibrium (r²) of each SNP with the top SNP in the region is indicated by its color. Crossed points represent imputed SNPs, circles represent directly genotyped SNPs.



Supplementary Figure 5. Comparison of shared FDR-significant genetic correlations between

161 lifetime cannabis use and frequency of cannabis use. Traits with discordant genetic correlation

162 directions of effect located in gray quadrants. Dotted lines represent point of full linearity

163 between lifetime and frequency of cannabis use. *reverse coded traits.

168 **References**

Bryc, K., Durand, E.Y., Macpherson, J.M., Reich, D., and Mountain, J.L. (2015). The
 genetic ancestry of African Americans, Latinos, and European Americans across the

171 United States. Am J Hum Genet *96*, 37-53. 10.1016/j.ajhg.2014.11.010.

- 172 2. National Academies of Sciences, Engineering, and Medicine Health and Medicine
- 173 Division, Division of Behavioral and Social Sciences and Education, Board on Health
- 174 Sciences Policy, Committee on Population, Committee on the Use of Race, and
- 175 Ethnicity, and Ancestry as Population Descriptors in Genomics Research (2023). In
- Using Population Descriptors in Genetics and Genomics Research: A New Framework
 for an Evolving Field. 10.17226/26902.
- 178 3. Durand, E.Y., Do, C.B., Mountain, J.L., and Macpherson, J.M. (2014). Ancestry
- 179 Composition: A Novel, Efficient Pipeline for Ancestry Deconvolution. bioRxiv. [Preprint].
 180 10.1101/010512.
- 181 4. Eriksson, N., Macpherson, J.M., Tung, J.Y., Hon, L.S., Naughton, B., Saxonov, S., Avey,
- 182 L., Wojcicki, A., Pe'er, I., and Mountain, J. (2010). Web-based, participant-driven studies
 183 yield novel genetic associations for common traits. PLoS Genet *6*, e1000993.
- , ,
- 184 10.1371/journal.pgen.1000993.
- 185 5. Hyde, C.L., Nagle, M.W., Tian, C., Chen, X., Paciga, S.A., Wendland, J.R., Tung, J.Y.,
- 186 Hinds, D.A., Perlis, R.H., and Winslow, A.R. (2016). Identification of 15 genetic loci
- 187 associated with risk of major depression in individuals of European descent. Nat Genet
- 188 *48*, 1031-1036. 10.1038/ng.3623.
- 189 6. Barkley-Levenson, A.M., Lagarda, F.A., and Palmer, A.A. (2018). Glyoxalase 1 (GLO1)
- 190 Inhibition or Genetic Overexpression Does Not Alter Ethanol's Locomotor Effects:
- 191 Implications for GLO1 as a Therapeutic Target in Alcohol Use Disorders. Alcohol Clin
- 192 Exp Res *42*, 869-878. 10.1111/acer.13623.

193	7.	Distler, M.G., Plant, L.D., Sokoloff, G., Hawk, A.J., Aneas, I., Wuenschell, G.E., Termini,
194		J., Meredith, S.C., Nobrega, M.A., and Palmer, A.A. (2012). Glyoxalase 1 increases
195		anxiety by reducing GABAA receptor agonist methylglyoxal. J Clin Invest 122, 2306-
196		2315. 10.1172/JCI61319.
197	8.	Henn, B.M., Hon, L., Macpherson, J.M., Eriksson, N., Saxonov, S., Pe'er, I., and
198		Mountain, J.L. (2012). Cryptic distant relatives are common in both isolated and
199		cosmopolitan genetic samples. PLoS One 7, e34267. 10.1371/journal.pone.0034267.
200	9.	Sanchez-Roige, S., Fontanillas, P., Elson, S.L., 23andMe Research Team, Pandit, A.,
201		Schmidt, E.M., Foerster, J.R., Abecasis, G.R., Gray, J.C., de Wit, H., et al. (2018).
202		Genome-wide association study of delay discounting in 23,217 adult research
203		participants of European ancestry. Nat Neurosci 21, 16-18. 10.1038/s41593-017-0032-x.
204	10.	Sanchez-Roige, S., Fontanillas, P., Jennings, M.V., Bianchi, S.B., Huang, Y., Hatoum,
205		A.S., Sealock, J., Davis, L.K., Elson, S.L., 23andMe Research Team, and Palmer, A.A.
206		(2021). Genome-wide association study of problematic opioid prescription use in
207		132,113 23andMe research participants of European ancestry. Mol Psychiatry 26, 6209-
208		6217. 10.1038/s41380-021-01335-3.
209	11.	Sanchez-Roige, S., Jennings, M.V., Thorpe, H.H.A., Mallari, J.E., van der Werf, L.C.,
210		Bianchi, S.B., Huang, Y., Lee, C., Mallard, T.T., Barnes, S.A., et al. (2023). CADM2 is
211		implicated in impulsive personality and numerous other traits by genome- and phenome-
212		wide association studies in humans and mice. Transl Psychiatry 13, 167.
213		10.1038/s41398-023-02453-y.
214	12.	Sanchez-Roige, S., Palmer, A.A., Fontanillas, P., Elson, S.L., 23andMe Research Team,
215		Substance Use Disorder Working Group of the Psychiatric Genomics Consortium,
216		Adams, M.J., Howard, D.M., Edenberg, H.J., Davies, G., et al. (2019). Genome-Wide
217		Association Study Meta-Analysis of the Alcohol Use Disorders Identification Test

218 (AUDIT) in Two Population-Based Cohorts. Am J Psychiatry *176*, 107-118.

219 10.1176/appi.ajp.2018.18040369.

- Fuchsberger, C., Abecasis, G.R., and Hinds, D.A. (2015). minimac2: faster genotype
 imputation. Bioinformatics *31*, 782-784. 10.1093/bioinformatics/btu704.
- Lee, S.H., Goddard, M.E., Wray, N.R., and Visscher, P.M. (2012). A better coefficient of
 determination for genetic profile analysis. Genet Epidemiol *36*, 214-224.

224 10.1002/gepi.21614.

- 225 15. Substance Abuse and Mental Health Services Administration. (2023). Results from the
 226 2022 National Survey on Drug Use and Health: Detailed tables.
- 16. Hasin, D.S., Kerridge, B.T., Saha, T.D., Huang, B., Pickering, R., Smith, S.M., Jung, J.,

Zhang, H., and Grant, B.F. (2016). Prevalence and Correlates of DSM-5 Cannabis Use

Disorder, 2012-2013: Findings from the National Epidemiologic Survey on Alcohol and

- 230 Related Conditions-III. Am J Psychiatry *173*, 588-599. 10.1176/appi.ajp.2015.15070907.
- 231 17. Pruim, R.J., Welch, R.P., Sanna, S., Teslovich, T.M., Chines, P.S., Gliedt, T.P.,
- Boehnke, M., Abecasis, G.R., and Willer, C.J. (2010). LocusZoom: regional visualization
- of genome-wide association scan results. Bioinformatics *26*, 2336-2337.
- 234 10.1093/bioinformatics/btq419.
- 235 18. Pasman, J.A., Verweij, K.J.H., Gerring, Z., Stringer, S., Sanchez-Roige, S., Treur, J.L.,

Abdellaoui, A., Nivard, M.G., Baselmans, B.M.L., Ong, J.S., et al. (2018). GWAS of

- 237 lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a
- causal influence of schizophrenia. Nat Neurosci 21, 1161-1170. 10.1038/s41593-018-

239 0206-1.

- 240 19. Levey, D.F., Galimberti, M., Deak, J.D., Wendt, F.R., Bhattacharya, A., Koller, D.,
- 241 Harrington, K.M., Quaden, R., Johnson, E.C., Gupta, P., et al. (2023). Multi-ancestry
- 242 genome-wide association study of cannabis use disorder yields insight into disease

- biology and public health implications. Nat Genet *55*, 2094-2103. 10.1038/s41588-023-
- 244 01563-z.